Study to Assess Safety and Use of ABR2 Eye Drops for Relieving Dry Eye Discomfort

What this Trial Is About

Researchers are evaluating the safety and tolerability of a new eye drop called ABR2, designed to provide temporary relief from dryness-related eye discomfort. This study targets adults with dry eye syndrome and involves two parts to assess short-term and longer use effects. The goal is to understand how well ABR2 is tolerated when used briefly and over a month. In the first part, participants receive a single drop of ABR2 in one eye and are monitored over an hour. In the second part, participants apply one drop at least twice daily, up to four times as needed, for 28 days. This study has no placebo group and is open-label, meaning all participants use ABR2. Part 1 involves two visits, while Part 2 includes six visits spread over several weeks. Participants will attend scheduled visits for screening, treatment, and follow-up assessments lasting a few hours each. Researchers will evaluate safety by recording any adverse events after the single dose and after 28 days of use. Measurements include eye examinations and symptom questionnaires. The study lasts about one month for Part 2, with close monitoring throughout the treatment period.

Evaluation of a Novel Ocular Lubricating Eye Drop